Cambridge Research Biochemicals, an independent producer of custom-made peptide and antibody tools, has announced that under the terms of a new contract with Leidos Biomedical Research, it will support the evaluation of a new treatment approach for Fuchs Dystrophy.
Glaucoma
Fuchs Dystrophy is an inherited disease that typically affects middle-aged patients that progresses slowly. It causes a gradual loss of vision that eventually requires treatment.
Under the terms of this new contract, Cambridge Research Biochemicals will develop reagents for use in the evaluation of eFGF-1, which is a compound that can promote the repair and regeneration of damaged tissues.
“We are delighted to be awarded the contract and look forward to a long and prosperous relationship with these US-based organisations,” said CRB commercial director Emily Humphrys. “It is an honour for a British company to be awarded this contract, and we are keen to delight a new client once again with our skills and expertise.”
“NCATS is committed to finding novel therapies for rare and neglected diseases. We will apply our knowledge of biopharmaceutical product development to this novel ophthalmic therapy by developing an ultrasensitive and specific bioanalytical method for TTHX-1114, as well as immunogenicity assessment methods,” said Erik Wagner, who along with Xin Xu and Philip Sanderson are the scientific leads for the project at National Center for Advancing Translational Sciences’ Therapeutics for Rare and Neglected Diseases — NCATS/TRND.